Robert E. Landry - Jan 31, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Jan 31, 2024
Transactions value $
-$117,272
Form type
4
Date filed
2/2/2024, 04:02 PM
Previous filing
Jan 25, 2024
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $152K +400 +1.71% $378.98 23.9K Jan 31, 2024 Direct
transaction REGN Common Stock Tax liability -$269K -282 -1.18% $953.42 23.6K Jan 31, 2024 Direct
holding REGN Common Stock 270 Jan 31, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -400 -3.18% $0.00 12.2K Jan 31, 2024 Common Stock 400 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.